Brickell is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases.

OUR RESEARCH

Pipeline
Our current pipeline consists of new molecular entities with relevant mechanisms of action in skin diseases, targeting significant market opportunities in the global dermatology market.

 

VIEW PIPELINE
Therapeutic Areas
Our current pipeline consists of new molecular entities targeting the treatment of the following indications:
  • Hyperhidrosis
  • Cutaneous T-cell Lymphoma
  • Allergic Contact Dermatitis
  • Psoriasis
  • Androgenic Alopecia

 

LEARN MORE

NEWS

News
November 19, 2018

Brickell Biotech Appoints Top Lilly Executive, Robert Brown, As Chief Executive Officer

Notable leadership change comes as Brickell prepares to progress its lead product candidate, sofpironium bromide, to Phase 3 clinical trials in primary axillary hyperhidrosis (excessive underarm sweating) BOULDER, CO, November…
News
February 20, 2018

Phase 2b Study Results Presented at the 76th American Academy of Dermatology Annual Meeting at the Late-Breaking Research Forum

SAN DIEGO, CA, February 20, 2018 – Brickell Biotech, Inc. (Brickell), a clinical-stage medical dermatology company, today announced that the positive confirmatory Phase 2b study (CL-203) results with sofpironium bromide…
News
October 24, 2017

Brickell Biotech Announces Positive, Statistically Significant Results of its Confirmatory Phase 2b Study of Sofpironium Bromide for the Topical Treatment of Primary Axillary Hyperhidrosis.

Statistically significant outcomes guide plan for Phase 3 development of sofpironium bromide in 2018 More than 15 million Americans, or 4.8% of the U.S. population, live with excessive sweating1 Boulder,…
ALL NEWS